SCHEMBL6818059

SCHEMBL6818059

COc1ccc(Oc2c(Cl)cc(N)cc2Cl)cc1C(C)C

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RORC P51449 11/20 0.70
THRB P10828 10/20 0.70
THRA P10827 5/20 0.47
P2RX3 P56373 1/20 0.43
P2RX2 Q9UBL9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221389 0.87 THRB (0.57) RORCTHRBTHRA
SCHEMBL22959261 0.86 THRB (0.70) RORCTHRBTHRA
SCHEMBL14264315 0.85 RORC (0.62) RORCTHRBTHRAP2RX3P2RX2
SCHEMBL8893247 0.84 THRB (0.57) RORCTHRBTHRAP2RX3P2RX2
SCHEMBL282017 0.84 THRB (0.53) RORCTHRBTHRAP2RX3P2RX2
SCHEMBL22959356 0.83 RORC (0.67) RORCTHRBTHRA
SCHEMBL281885 0.83 THRB (0.79) RORCTHRBTHRA
Hydrochloric Acid SCHEMBL8800518 0.83 THRB (0.52) RORCTHRBTHRAP2RX3P2RX2
SCHEMBL7069261 0.82 THRB (0.77) RORCTHRBTHRA
SCHEMBL282442 0.82 THRB (1.00) RORCTHRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220306630-A1 AGONISTS OF ROR GAMMAt BRISTOL MYERS SQUIBB CO (US) 2022-09-29 US claimed
WO-2021026179-A1 AGONISTS OF ROR GAMMAt BRISTOL-MYERS SQUIBB COMPANY (US) 2021-02-11 WO claimed
US-20220306630-A1 AGONISTS OF ROR GAMMAt BRISTOL MYERS SQUIBB CO (US) 2022-09-29 US disclosed
WO-2021026179-A1 AGONISTS OF ROR GAMMAt BRISTOL-MYERS SQUIBB COMPANY (US) 2021-02-11 WO disclosed
WO-2021026179-A1 AGONISTS OF ROR GAMMAt BRISTOL-MYERS SQUIBB COMPANY (US) 2021-02-11 WO disclosed
WO-2004018421-A1 IDOL DERIVATIVES AS NEW THYROID RECEPTOR AGONIST LIGANDS AND METHODS KARO BIO AB. (SE) 2004-03-04 WO disclosed
EP-0580550-B1 Oxamic acid derivatives as hypocholesteremic agents CIBA GEIGY AG (CH) 1997-10-22 EP disclosed
US-5654468-A ANTILIPID, ANTICHOLESTEROL AGENTS CIBA-GEIGY CORPORATION (US) 1997-08-05 US disclosed
US-5569674-A ANTICHOLESTEROL AGENTS CIBA-GEIGY CORPORATION (US) 1996-10-29 US disclosed
US-5401772-A Anticholesterol agents with aromatic amines CIBA-GEIGY CORPORATION (US) 1995-03-28 US disclosed
EP-0580550-A1 Oxamic acid derivatives as hypocholesteremic agents CIBA-GEIGY AG (CH) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306630-A1 AGONISTS OF ROR GAMMAt RORB, RORA, RORC RORC 3/4885THRB 44/4885THRA 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.